Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Monumental Year Ahead For Korean Pharmas As New US Approvals Eyed

Jan 10 2019

• By Jung Won Shin

New year 2019 3d rendering. - Illustration — Korean Pharma Outlook for 2019 • Source: Shutterstock

Related Content

Spectrum To Test Poziotinib's Potential As First Line Treatment Of Exon 20 Mutant NSCLC

Sep 19 2018

AbbVie Defends Humira With Aggressive Discount In First EU Tender

Nov 01 2018

Committing To Drug Development In World's Biggest Market: SK's Story

Mar 13 2018

Spectrum Gears Up To File Rolontis, Stresses Patient Access

Jul 02 2018

ViroMed's Plasmid DNA Facility Buy Addresses Key Potential US Regulatory Hurdle

Jul 23 2018

BIO Korea 2016: SillaJen On Maximizing Value Of Pexa-Vec

Apr 13 2016

Related Companies

SK Biopharmaceuticals Co., Ltd

Jazz Pharmaceuticals plc

Hanmi Pharmaceutical Co., Ltd.

Spectrum Pharmaceuticals, Inc.

Helixmith Co., Ltd.

SillaJen, Inc

Regeneron Pharmaceuticals, Inc.

Lee's Pharmaceutical Holdings Limited

Transgene S.A.

Novo Nordisk A/S

Sanofi

AbbVie Inc.

Additional Topics

South Korea Asia Pacific Commercial Outlook 2019 BioPharmaceutical

More from South Korea

More from Focus On Asia

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window